The Indian government wants to update its procurement rules for medical devices. Specifically, the Department of Pharmaceuticals has requested industry feedback to revise the existing GTE exemption list. Therefore, public agencies can import these critical items when local options are unavailable. The department has set a deadline of July 15, 2026, for public comments. Consequently, healthcare providers and manufacturers must evaluate these proposed changes immediately.

Understanding the Purpose of the GTE exemption list

Public procurement policies in India strongly favor domestic manufacturers. Under the 'Make in India' initiative, public agencies must prioritize locally produced medical devices. However, local companies do not yet manufacture some advanced medical technologies in India. To address this challenge, the Finance Ministry amended the General Financial Rules. This amendment permits global tenders for select products up to Rs 200 crore. The GTE exemption list provides a vital regulatory pathway for importing these critical items. Currently, the standing list contains 354 exempted medical devices. The government launched the review process in February this year. Ultimately, the goal is to balance self-reliance with immediate clinical needs. This review ensures that government hospitals can buy high-quality equipment without delay. Additionally, it helps local manufacturers understand where supply gaps exist. Consequently, this policy directly impacts patient care across the country. By refining the list, the government aims to create a transparent procurement process. Furthermore, clear rules prevent administrative confusion during large public tenders. Therefore, both domestic and international companies closely monitor these regulatory updates. These guidelines will shape future medical access.

Proposed Additions: Enhancing Healthcare Infrastructure

The government has received numerous representations to expand the current exemptions. Specifically, stakeholders have requested the inclusion of 350 new devices on the list. These proposed additions contain highly specialized clinical equipment. For instance, epidural anesthesia kits and bedside ultrasound systems are on the request list. Furthermore, multi-modal vacuum wound healing systems and 1.5 Tesla MRI scanners require exemptions. Currently, Indian companies do not manufacture these sophisticated devices in high volumes. Consequently, hospitals must import them to maintain high standards of patient care. Importing these devices allows medical practitioners to use the latest diagnostic tools. Indeed, access to advanced imaging systems improves clinical outcomes significantly. Without these exemptions, public procurement agencies would face severe delays. Therefore, global device manufacturers strongly welcome these proposed additions. They argue that these technologies are essential for saving lives. Additionally, these imports support critical care departments in government medical colleges. Healthcare administrators must monitor these updates to plan future equipment purchases. Ultimately, the finalized list will shape hospital budgets for the coming years. This proactive planning prevents shortages in public clinics.

Domestic Production Gains and Requested Deletions

In contrast, domestic manufacturers are pushing to remove several products from the list. Specifically, stakeholders have requested the exclusion of 235 products. These items include digital subtraction angiography systems and intraoperative radiotherapy machines. Additionally, surgical navigation systems are also on the deletion list. Local manufacturers argue that domestic production of these items has improved significantly. Furthermore, companies have committed substantial capital to build local manufacturing units. Consequently, they want the government to protect their investments. Forcing public agencies to buy locally will boost the domestic industry. This step aligns perfectly with the 'Make in India' vision. However, global suppliers express concern over sudden exclusions. They believe that local manufacturing must prove its quality first. Nevertheless, the government must evaluate actual domestic capacity before making changes. If local supply is sufficient, removing these items is highly logical. This approach will encourage further domestic research and development. Ultimately, a balanced decision will protect both local businesses and patients. Therefore, the upcoming review on July 15 is extremely critical. Industry leaders must present strong, evidence-based data to support their positions.

Balancing Industry Demands and Regulatory Gestation

Finding a middle ground remains a complex challenge for the Department of Pharmaceuticals. For instance, multinational device makers want a comprehensive, evidence-based framework. They emphasize that patient safety must remain the top priority. Meanwhile, domestic groups highlight the long gestation periods for high-risk products. Specifically, obtaining manufacturing approvals for Class C and D devices takes 9 to 15 months. During this long period, companies struggle to manage fixed costs. Therefore, they need guaranteed public procurement shares to survive. Currently, India depends heavily on imported medical devices. Imports currently fulfill around 80 to 85 percent of the total requirement. In FY26, imports surged 17 percent year-on-year to Rs 89,000 crore. Technology-intensive products largely drove this massive surge. Consequently, reducing this import dependency is an urgent national priority. However, sudden import bans could hurt patient care in government hospitals. Thus, the government must design a gradual transition plan. This plan will give domestic firms time to scale up production. Ultimately, this approach will ensure a steady supply of high-quality devices. Promoting local alternatives strengthens the national healthcare ecosystem.

The Economic and Clinical Implications for Indian Healthcare

The ongoing revision of the GTE exemption list will have lasting economic effects. Specifically, it will dictate the flow of foreign medical technology into public hospitals. If the government removes too many items, import costs might rise for private players. Conversely, public hospitals might face shortages of cutting-edge diagnostic tools. Therefore, policymakers must analyze empirical data on domestic production. Healthcare administrators also need to prepare for potential procurement shifts. For example, hospitals may need to update their supplier databases. Additionally, they must train staff to use newly approved domestic alternatives. This training ensures that clinical quality remains high. Furthermore, local manufacturers must meet global certification standards. If they fail to do so, healthcare quality could suffer. Consequently, clinical research and trials are crucial for establishing domestic credibility. Ultimately, a successful policy will foster a robust medical ecosystem in India. This ecosystem will benefit patients, doctors, and manufacturers alike. Indeed, India has the potential to become a global hub for medical device manufacturing. Thus, this regulatory exercise is a stepping stone toward that goal. Continuous feedback remains essential.

Frequently Asked Questions

Q1: What is the primary purpose of the GTE exemption list for medical devices in India?

The GTE exemption list allows public agencies and government hospitals to bypass local sourcing mandates. Normally, 'Make in India' guidelines require buying locally manufactured products. However, some advanced technologies are unavailable locally. By placing these devices on this exemption list, the government permits overseas procurement for select tenders. This ensures patients can access critical diagnostic and therapeutic tools without delay.

Q2: Why are domestic manufacturers asking to remove certain devices from this list?

Domestic manufacturers request deletions because local production capacity has improved significantly. Companies have committed capital to build factories and obtain test licenses for advanced equipment. Consequently, they believe India can supply these products domestically. Removing them from the list forces agencies to prioritize local products first. This protective policy supports local business growth and reduces import dependency.

Q3: How can stakeholders submit their feedback regarding these proposed amendments?

Stakeholders must submit their comments or objections on or before July 15, 2026. They need to send feedback via email to the Department of Pharmaceuticals. Additionally, submissions must include supporting data. This data covers manufacturing capacity, production volumes, and standards. The department will review all representations to ensure the final list matches national capabilities.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.

References

1. Centre seeks Industry feedback over revision of GTE-Exempt Medical device list - ETHealthworld


2. Department of Pharmaceuticals Invites Stakeholder Comments on Proposed Amendments to the GTE Exemption List of Medical Devices - PIB


3. Govt begins review of GTE exemption list for medical devices - The Financial Express